title: Clinical trials of stereotactic ablative radiotherapy for prostate cancer: updates and future direction.
abstract: Stereotactic body radiotherapy, also known as stereotactic ablative body radiotherapy (SABR), is an emerging treatment option for lung, prostate, liver and other tumors. Key factors in SABR are delivery of a high-dose radiation per fraction, proper patient positioning and target localization. Our review details the various radiotherapy techniques, dose fractionation schedules and toxicities for prostate SABR. Ongoing Phase II/III SABR studies across various risk groups have been included. It also discusses the role of conscientious focal dose escalation of the dominant intraprostatic nodule, integrating multiparametric MRI into radiotherapy protocols and finally cost-effectiveness of SABR.
authors.affiliation: Odette Cancer Centre, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Toronto, ON, M4N 3M5, Canada.
authors.forename: H Bindu
authors.initials: HB
authors.lastname: Musunuru
authors.forename: Andrew
authors.initials: A
authors.lastname: Loblaw
mesh_terms: D002986:Clinical Trials as Topic; D019583:Dose Fractionation, Radiation; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000175:diagnosis / Q000401:mortality / Q000532:radiotherapy* / Q000601:surgery*; D011829:Radiation Dosage; D016634:Radiosurgery / Q000009:adverse effects / Q000379:methods*; D065287:Robotic Surgical Procedures; D016896:Treatment Outcome
keywords: image-guided radiotherapy; prostate cancer; quality of life; stereotactic ablative radiotherapy